• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Industry Calls for Action on Drug-Resistant Infections


January 21, 2015.

More than 80 pharma companies and organizations have called on industry and governments worldwide for action to combat drug-resistant infections.

The top ten pharma companies are among those that have signed the Declaration on Combating Antimicrobial Resistance (AMR)announced at the World Economic Forum in Davos, Switzerland. The declaration outlines how industry and governments can work together to support sustained innovation to address the growing problem of AMR.

The independent UK 

Review on Antimicrobial Resistance

 estimates that without effective global action, the rise of drug-resistant infections could claim 10 million lives globally each year by 2050 and result in a cumulative loss from global output of 100 trillion USD. The Declaration outlines three areas in which the companies will work to prevent and treat drug-resistant infections: reduce drug resistance through appropriate use of new and existing antibiotics; increase investment and collaboration in research and development; and improve access to high-quality antibiotics.



Related Videos